Author Index

(BR): Book Review
(L): Letter to the Editor

A
Abken, H., Hombach, A., Reinhold, U. and Ferrone, S., Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? 2
Adorini, L., *see* Revillard, J-P. 291
Agarwal, S.S. and Naik, S., Current trends in autoimmune diseases 436
Agea, E., *see* Spinozzi, F. 22
Aiuti, F., *see* Paganelli, R. (L) 142
Alexandroff, A.B., Robins, R.A., Murray, A. and James, K., Tumour immunology: false hopes – new horizons? 247
Alves, L.A., Campos de Carvalho, A.C. and Savino, W., Gap junctions: A novel route for cell–cell communication in the immune system? 269
Anderson, A.O., *see* Rosenberg, Y.J. 10
Anderton, S.M., *see* van Eden, W. 303
Angelisova, P., *see* Horejsi, V. (L) 486
Antonarakis, S.E., *see* Peterson, P. 384
Appelmelk, B.J., Faller, G., Claeys, D., Kirschner, T. and Vandenbrouke-Grauls, C.M.J.E., Bugs on trial: the case of *Helicobacter pylori* and autoimmunity 296
Asadullah, K., *see* Jahn, S. 100

B
Barnes, K.C. and Marsh, D.G., The genetics and complexity of allergy and asthma 325
Barsoum, A.L., *see* Coggin Jr., J.H. 405
Barth, R.K., *see* Ostberg, J.R. 546
Battistini, L., *see* Poccia, F. 253
Beckett, G.J., *see* McKenzie, R.C. 342
Bell, E.B., Sparshott, S.M. and Bunce, C., $CD4^+$ T-cell memory, CD45R subsets and the persistence of antigen – a unifying concept 60
Bellone, M., *see* Protti, M.P. (L) 98
Bendtzen, K., Hansen, M.B., Ross, C. and Svenson, M., High-avidity autoantibodies to cytokines 209
Bennett, S.R.M., *see* Carbone, F.R. 368
Berek, C., *see* Camacho, S.A. 511
Bergquist, J., Tarkowski, A., Ewing, A. and Ekman, R., Catecholaminergic suppression of immunocompetent cells 562
Bertotto, A., *see* Spinozzi, F. 22
Bistoni, O., *see* Spinozzi, F. 22
Blalock, J.E., β-endorphin in immune cells (L) 191
Blanca, M., *see* Coleman, J.W. 196
Bode, U., *see* Westerman, J. (L) 143
Bona, C.A., Casares, S. and Brumeau, T-D., Towards development of T-cell vaccines 126
Bonifer, C., Faust, N., Geiger, H. and Müller, A.M., Developmental changes in the differentiation capacity of haematopoietic stem cells 236
Bonneville, M., *see* Poccia, F. 253
Borghans, J.A.M. and de Boer, R.J., Crossreactivity of the T-cell receptor (L) 428
Borrebaeck, C.A.K., Tapping the potential of molecular libraries in functional genomics 524
Bosch, X., Alternative non-steroidal anti-inflammatory therapy for asthma (L) 429
Bottazzo, G., *see* Mirakian, R. (L) 97
Brady, M.T., Mahon, B.P. and Mills, K.H.G., Pertussis infection and vaccination induces Th1 cells (L) 534
Braun, J., *see* Fairhurst, R.M. 257
Brenner, M.B., *see* Porcelli, S.A. 362
Brickett, P.M., *see* Thrasher, A.J. 537
Brines, R., Bim bang in cell death 99
Brines, R., BLC: the emergence of a B-cell chemokine 147
Brines, R., Brain damage: the case for astrocyte-derived perforin 147
Brines, R., Broad rejection: epitope spreading in heart transplant intolerance 99
Brines, R., Case proven? Melanoma vaccines on trial 195
Brines, R., CD14: the silent reaper? 243
Brines, R., Endothelial cells 'present' chemokines during inflammation 1
Brines, R., Friend or foe? Caspase-mediated subversion of Bcl-2 53
Brines, R., HLA class II peptide editing: DO downregulates DM 53
Brines, R., Inflammation not imitation in virally inducted diabetes 383
Brines, R., Intraepithelial versus thymic lymphocyte selection 383
Brines, R., LT-α-expressing B cells in development of lymphoid follicles 243
Brines, R., Magic marker? Stable expression of STL2 on Th2 cells 195
Brines, R., Rules of engagement: TCR signals dissected 337
Brines, R., 'Scanning' recognition by TCRs 147
Brines, R., Skin kin: PSGL-1 becomes CLA for dermal homing 1
Brock, J.H., Immunology (8th edition) (BR) 335
Brown, K.L., *see* Mabbott, N.A. 201
Bruce, M.E., *see* Mabbott, N.A. 201
Bruijnzeel-Koomen, C.A.F.M., *see* Grewe, M. 359
Brumeau, T-D., *see* Bona, C.A. 126
Bunce, C., *see* Bell, E.B. 60
Burgos-Vargas, R., The Spondylarthritides (BR) 430
Butcher, G.W., *see* Joly, E. 580

C
Calder, P.C., Fat chance of immunomodulation 244
Camacho, S.A., Kosco-Vilbois, M.H. and Berek, C., The dynamic structure of the germinal center 511
Campos de Carvalho, A.C., *see* Alves, L.A. 269
Cantin, R., *see* Tremblay, M.J. 346
Carbone, F.R., Kurts, C., Bennett, S.R.M., Miller, J.F.A.P. and Heath, W.R., Cross-presentation: a general mechanism for CTL immunity and tolerence 368
Casanova, J-L., *see* Ottenhoff, T.H.M. 491
Casares, S., *see* Bona, C.A. 126
Chen, E.H., Gadina, M., Galon, J., Chen, M. and O'Shea, J.J., Not just another meeting: the coming of age of JAKs and STATs 338
Chen, L., Immunological ignorance of silent antigens as an explanation of tumor evasion 27
Chen, M., *see* Chen, E.H. 338
Chen, Y-H. and Dierich, M.P., A common epitope on gp41, IFN-α and IFN-β induces protective activity (L) 586
Cheng, H-M., Cell penetration by antiphospholipid autoantibodies (L) 49
Choquet, G., *see* Krasteva, M. (L) 289
Claeys, D., *see* Appelmelk, B.J. 296
Coggin Jr., J.H., Barsoum, A.L. and Rohrer, J.W., Tumors express both unique TSTA and cross-protective 44kDa oncofetal antigen 405
Cohen, I.R., *see* Reizis, B. 212
Colaco, C., Acquired wisdom in innate immunity (L) 50
Coleman, J.W. and Blanca, M., Mechanisms of drug allergy 196
Colizzi, V., *see* Poccia, F. 253
Colomb, M.G., *see* Reid, K.B.M. 56
Cordero, O., *see* Lluis, C. (L) 533
Corr, M., *see* Tighe, H. 89
Cosimi, A.B., *see* Pascual, M. 514
Critchley, H.O.D., *see* Kelly, R.W. (L) 142

D
Dannecker, G.E., *see* Kümmerle-Deschner, J.B. 250
Dardenne, M., *see* Savino, W. (L) 144
Dawson, C.W., *see* Young, L.S. 502
de Boer, R.J., *see* Borghans, J.A.M. (L) 428
de Bruijn, M., *see* Dzierzak, E. 228

De Maria, R. and Testi, R., Fas–FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity 121
De Simone, C., *see* Famularo, G. (L) 486
Delovitch, T.L., *see* Salojin, K.V. 468
Díaz-González, F. and Sánchez-Madrid, F., Inhibition of leukocyte adhesion: an alternative mechanism of action for anti-inflammatory drugs 169
Dierich, M.P., *see* Chen, Y-H. (L) 586
Dimitrov, D.S., *see* Grossman, Z. 528
Dixit, V.M., *see* Froelich, C.J. 30
Doenhoff, M.J., Granulomatous inflammation and the transmission of infection: schistosomiasis – and TB too? 462
Dorling, A., *see* Rogers, N.J. 206
DosReis, G.A. and Shevach, E.M., Peripheral T-cell self-reactivity and immunological memory (L) 587
Downing, J.E.G., Virag, L. and Perry, M.E., Nitrergic mechanism of DC-mediated T-cell elimination (L) 190
Drbal, K., *see* Horejsi, V. (L) 486
Dunn-Walters, D.K., *see* Spencer, J. 421
Dzierzak, E., Medvinsky, A. and de Bruijn, M., Qualitative and quantitative aspects of haematopoietic cell development in the mammalian embryo 228

E
Eisenstein, M., *see* Reizis, B. 212
Ekman, R., *see* Bergquist, J. 562
Eliopoulos, A.G., *see* Young, L.S. 502
Elson, C.O., *see* Zierhut, M. 148
Ewing, A., *see* Bergquist, J. 562

F
Fairhurst, R.M., Wang, C-X., Sieling, P.A., Modlin, R.L. and Braun, J., CD1-restricted T cells and resistance to polysaccharide-encapsulated bacteria 257
Falk, W., *see* Straub, R.H. 409
Faller, G., *see* Appelmelk, B.J. 296
Famularo, G. and De Simone, C., Oral bacteriotherapy (L) 486
Farquhar, C.F., *see* Mabbott, N.A 201
Farzaneh, F., Trefzer, U., Sterry, W. and Walden, P., Gene therapy of cancer 294
Faust, N., *see* Bonifer, C. 236
Fazekas de St Groth, B., The evolution of self-tolerance: a new cell arises to meet the challenge of self-reactivity 448
Feinberg, M.B., *see* Grossman, Z. 528
Ferrone, S., *see* Abken, H. 2
Fibbe, W.E., *see* Opdenakker, G. 182
Fickenscher, H., *see* Meinl, E. 474
Fiorilli, M., *see* Paganelli, R. (L) 142
Fleckenstein, B., *see* Meinl, E. 474
Forenza, N., *see* Spinozzi, F. 22
Forrester, J.V., *see* Zierhut, M. 148
Fortin, C., *see* Perreault, C. 69
Fortin, J-F., *see* Tremblay, M.J. 346
Franco, R., *see* Lluis, C. (L) 533
Frelinger, J.G., *see* Ostberg, J.R. 546
Fricchione, G.L., *see* Stefano, G.B. 265
Friedman, H., *see* Klein, T.W. 373
Froelich, C.J., Dixit, V.M. and Yang, X., Lymphocyte granule-mediated apoptosis: matters of viral mimicry and deadly proteases 30
Fuchs, D., *see* Weiss, G. (L) 193

G
Gadina, M., *see* Chen, E.H. 338
Gallagher, N.J., *see* Young, L.S. 502
Galon, J., *see* Chen, E.H. 338
Garrido, F., *see* Ruiz-Cabello, F. 539
Gascoigne, N.R.J., *see* Sim, B.C. 276
Gay, S., *see* Jorgensen, C. 387
Geiger, H., *see* Bonifer, C. 236
Geuze, H.J., The role of endosomes and lysosomes in MHC class II functioning 282
Ghia, P., ten Boekel, E., Rolink, A.G. and Melchers, F., B-cell development: a comparison between mouse and man 480
Ghosh, S., *see* May, M.J. 80
Gibbins, J., *see* Watson, S.P. 260
Gleichmann, E., T Lymphocyte Subpopulations in Immunotoxicology (BR) 586
Gleichmann, E., *see* Griem, P. 133
Gobin, S.J.P., *see* van den Elsen, P.J. 308
Goldman, M., *see* Revillard, J-P. 291
Gonzalez, J.B., *see* Griem, P. 133
Gorski, A., Adhesion Molecules in Allergic Disease (BR) 50
Gougeon, M-L., *see* Poccia, F. 253
Goulmy, E., *see* Simpson, E. 108
Grabbe, S. and Schwarz, T., Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity 37
Green, W.R., *see* Mayrand, S-M. 551
Gregory, S.H. and Wing, E.J., Neutrophil–Kupffer-cell interaction in host defenses to systemic infections 507
Grewal, I.S., *see* Moudgil, K.D. 217
Grewe, M., Bruijnzeel-Koomen, C.A.F.M., Schöpf, E., Thepen, T., Langeveld-Wildschut, E.G., Ruzicka, T. and Krutmann, J., A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis 359
Griem, P., Wulferink, M., Sachs, B., Gonzalez, J.B. and Gleichmann, E., Allergic and autoimmune reactions to xenobiotics: how do they arise? 133
Griffioen, A.W., *see* Molema, G. 392
Grossman, Z., Feinberg, M.B., Kuznetsov, V., Dimitrov, D.S. and Paul, W.E., HIV infection: how effective is drug combination treatment? 528
Guardiola, J., MHC Volume 2: A Practical Approach (BR) 535
Gupta, S.K., The immunology of reproduction: update 1998 433

H
Hafler, D.A., *see* Martin, R. 495
Hammond, L.J., *see* Mirakian, R. (L) 97
Hansen, M.B., *see* Bendtzen, K. 209
Heath, W.R., *see* Carbone, F.R. 368
Heino, J., *see* Peterson, P. 384
Hemmer, B., Vergelli, M., Pinilla, C., Houghten, R. and Martin, R., Probing degeneracy in T-cell recognition using peptide combinatorial libraries 163
Hoffman, M.K., *see* Kümmerle-Deschner, J.B. 250
Holgate, S.T., IgE Regulation: Molecular Mechanisms (BR) 430
Hombach, A., *see* Abken, H. 2
Horejsi, V., Drbal, K. and Angelisova, P., A clustered subset of MHC class II molecule (L) 486
Horejsi, V., The Leucocyte Antigen FactsBook (2nd edn) (BR) 194
Houghten, R., *see* Hemmer, B. 163
Huang, Z., *see* Li, S. 455

I
Ingelfinger, J.R., *see* Pascual, M. 514

J
Jahn, S., Asadullah, K., Walden, P. and Sterry, W., Cutaneous malignant lymphomas 100
James, K., *see* Alexandroff, A.B. 247
Johnson, H., *see* Schiffenbauer, J. 117
Joly, E. and Butcher, G.W., Why are there two rat TAPs? 580
Jones, G.E., *see* Thrasher, A.J. 537
Jorgensen, C. and Gay, S., Gene therapy in osteoarticular diseases: where are we? 387

K
Kabelitz, D., *see* Revillard, J-P. 291
Kaiserlian, D., *see* Krasteva, M. (L) 289
Kappos, L., *see* Laman, J.D. 489
Katz, D.R., *see* Thrasher, A.J. 537
Kehren, J., *see* Krasteva, M. (L) 289
Kelly, R.W. and Critchley, H.O.D., T-cell modulation in decidua (L) 142
Kijlstra, A., *see* Zierhut, M. 148
Kinnon, C., *see* Thrasher, A.J. 537
Kirschner, T., *see* Appelmelk, B.J. 296
Klarlund Pedersen, B. and Nieman, D.C., Exercise immunology: integration and regulation 204
Klein, M.R., van der Burg, S.H., Pontesilli, O. and Miedema, F., Cytotoxic T lymphocytes in HIV-1 infection: a killing paradox? 317
Klein, T.W., Newton, C. and Friedman, H., Cannabinoid receptors and immunity 373
Kohler, H. and Paul, S., Superantibody activities: new players in innate and adaptive immune responses 221
Kolb, H. and Kolb-Bachofen, V., Nitric oxide in autoimmune disease: cytotoxic or regulatory mediator? 556

Kolb-Bachofen, V., *see* Kolb, H. 556
Korngold, R., *see* Li, S. 455
Kosco-Vilbois, M.H., *see* Camacho, S.A. 511
Kovarik, J. and Siegrist, C-A., Immunity in early life 150
Kraehenbuhl, J-P., *see* Zierhut, M. 148
Krasteva, M., Kehren, J., Choquet, G., Kaiserlian, D. and Nicolas, J-F., Dendritic-cell response in contact hypersensitivity (L) 289
Krohn, K., *see* Peterson, P. 384
Krutmann, J., *see* Grewe, M. 359
Kudoh, N., *see* Peterson, P. 384
Kumararatne, D., *see* Ottenhoff, T.H.M. 491
Kümmerle-Deschner, J.B., Hoffman, M.K., Niethammer, D. and Dannecker, G.E., Pediatric rheumatology: autoimmune mechanisms and therapeutic strategies 250
Kurts, C., *see* Carbone, F.R. 368
Kuznetsov, V., *see* Grossman, Z. 528

L
Laman, J.D., Thompson, E.J. and Kappos, L., Balancing the Th1/Th2 concept in multiple sclerosis 489
Lambert, R.D., Reproductive Immunology (BR) 51
Lambris, J.D., *see* Sunyer, J.O. 519
Lampson, L.A., Beyond inflammation: site-directed immunotherapy 17
Langeveld-Wildschut, E.G., *see* Grewe, M. 359
Lanzavecchia, A., *see* Sallusto, F. 568
LeClerc, C. and Ronco, J., New approaches in vaccine development 300
Lepault, F., *see* Savino, W. (L) 144
Leskovsek, N., *see* Rose, N.R. 499
Lew, A.M., *see* Martin, R.M. (L) 49
Li, S., Satoh, T., Korngold, R. and Huang, Z., CD4 dimerization and oligomerization: implications for T-cell function and structure-based drug design 455
Liew, F.Y., *see* McInnes, I.B. 75
Lluis, C., Franco, R. and Cordero, O., Ecto-ADA in the development of the immune system (L) 533
Lo, D., *see* Sim, B.C. 276
Lochs, H., *see* Stallmach, A. 438
Loos, M., *see* Reid, K.B.M. 56
Lôpez-Botet, M., *see* Poccia, F. 253

M
Mabbott, N.A, Farquhar, C.F., Brown, K.L. and Bruce, M.E., Involvement of the immune system in TSE pathogenesis 201
MacDonald, T.T., *see* Stallmach, A. 438
Mackay, C.R., *see* Sallusto, F. 568
Madrenas, J., *see* Salojin, K.V. 468
Mage, R.G., *see* Pospisil, R. 106
Magor, K.E. and Vasta, G.R., Ancestral immunity comes of age 54
Mahon, B.P., *see* Brady, M.T. (L) 534
Malkovsky, M., *see* Poccia, F. 253
Mandel, T.E., *see* Smith, R.M. 444
Marone, G., Asthma: recent advances 5
Marsh, D.G., *see* Barnes, K.C. 325
Martin, J., *see* Tobes, R. (L) 192
Martin, R., *see* Hemmer, B. 163
Martin, R., Ruddle, N.H., Reingold, S.C. and Hafler, D.A., T helper cell differentiation in multiple sclerosis and autoimmunity 495
Martin, R.M. and Lew, A.M., Is IgG2a a good Th1 marker in mice? (L) 49
Mason, D., A very high level of cross-reactivity is an essential feature of the T-cell receptor 395
Mathisen, P.M. and Tuohy, V.K., Gene therapy in the treatment of autoimmune disease 103
May, M.J. and Ghosh, S., Signal transduction through NF-κB 80
Mayrand, S-M. and Green, W.R., Non-traditionally derived CTL epitopes: exceptions that prove the rules? 551
McCormack, K., Idiotype vaccines 337
McCormack, K., TCRζ phosphorylation determines T-cell activation 383
McInnes, I.B. and Liew, F.Y., Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis 75
McKenzie, R.C. and Weller, R., Langerhans cells, keratinocytes, nitric oxide and psoriasis (L) 427
McKenzie, R.C., Rafferty, T.S. and Beckett, G.J., Selenium: an essential element for immune function 342
Medvinsky, A., *see* Dzierzak, E. 228
Mehra, N., The major histocompatibility complex – progress and perspectives 434
Meinl, E., Fickenscher, H., Thome, M., Tschopp, J. and Fleckenstein, B., Anti-apoptotic strategies of lymphotropic viruses 474
Melchers, F., *see* Ghia, P. 480
Melchers, F., *see* Osmond, D.G. 65
Michie, C., Th1 and Th2 cytokines in pregnancy, from a fetal viewpoint (L) 333
Miedema, F., *see* Klein, M.R. 317
Miedema, F., *see* Wolthers, K.C. 44
Miller, J.F.A.P., *see* Carbone, F.R. 368
Mills, K.H.G., *see* Brady, M.T. (L) 534
Mingari, M.C., Moretta, A. and Moretta, L., Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses 153
Mirakian, R., Hammond, L.J. and Bottazzo, G., Pathogenesis of thyroid autoimmunity: the Bottazzo–Feldman hypothesis (L) 97
Modlin, R.L., *see* Fairhurst, R.M. 257
Molema, G. and Griffioen, A.W., Rocking the foundations of solid tumor growth by attacking the tumor's blood supply 392
Moore, M., *see* Rogers, N.J. 206
Mor, F., *see* Reizis, B. 212
Moretta, A., *see* Mingari, M.C. 153
Moretta, A., *see* Poccia, F. 253
Moretta, L., *see* Mingari, M.C. 153
Morhenn, V., Langerhans cells, keratinocytes, nitric oxide and psoriasis: reply to McKenzie (L) 427
Moudgil, K.D., Sercarz, E.E. and Grewal, I.S., Modulation of the immunogenicity of antigenic determinants by their flanking residues 217
Mowat, A. McI., *see* Strobel, S. 173
Müller, A.M., *see* Bonifer, C. 236
Murray, A., *see* Alexandroff, A.B. 247
Murray, J.S., How the MHC selects Th1/Th2 immunity 157

N
Nagamine, K., *see* Peterson, P. 384
Naik, S., *see* Agarwal, S.S. 436
Nechushtan, H. and Razin, E., Deciphering the early-response transcription factor networks in mast cells 441
Newton, C., *see* Klein, T.W. 373
Nicolas, J-F., *see* Krasteva, M. (L) 289
Nieman, D.C., *see* Klarlund Pedersen, B. 204
Niethammer, D., *see* Kümmerle-Deschner, J.B. 250
Nieto, A., *see* Tobes, R. (L) 192

O
O'Shea, J.J., *see* Chen, E.H. 338
Oettgen, H.C., Cytokine Knockouts (BR) 487
Opdenakker, G., Fibbe, W.E. and Van Damme, J., The molecular basis of leukocytosis 182
Osmond, D.G., Rolink, A. and Melchers, F., Murine B lymphopoiesis: towards a unified model 65
Ostberg, J.R., Barth, R.K. and Frelinger, J.G., The Roman god Janus: a paradigm for the function of CD43 546
Ottenhoff, T.H.M., Kumararatne, D. and Casanova, J-L., Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria 491

P
Pabst, R., *see* Rosenberg, Y.J. 10
Pabst, R., *see* Westerman, J. (L) 143
Paganelli, R., Scala, E., Aiuti, F. and Fiorilli, M., B-cell help by Tc2 cells (L) 142
Panayi, G., Therapy of Systemic Rheumatic Disorders (BR) 382
Panerai, A.E. and Sacerdote, P., β-endorphin in immune cells: reply to Blalock (L) 192

Papadopoulos, G.K., Genetics of type I diabetes (L) 288
Pareja, E., *see* Tobes, R. (L) 192
Pascual, M., Swinford, R.D, Ingelfinger, J.R., Williams, W.W., Cosimi, A.B. and Tolkoff-Rubin, N., Chronic rejection and chronic cyclosporin toxicity in renal allografts 514
Paul, A.G.A., *see* van Eden, W. 303
Paul, S., *see* Kohler, H. 221
Paul, W.E., *see* Grossman, Z. 528
Peijnenburg, A., *see* van den Elsen, P.J. 308
Perreault, C., Roy, D.C. and Fortin, C., Immunodominant minor histocompatibility antigens: the major ones 69
Perry, M. and Whyte, A., Immunology of the tonsils 414
Perry, M.E., *see* Downing, J.E.G. (L) 190
Perry, M.E., *see* Spencer, J. 421
Peterson, P., Nagamine, K., Scott, H., Heino, J., Kudoh, N., Shimizu, N., Antonarakis, S.E. and Krohn, K., APECED: a monogenic autoimmune disease providing new clues to self tolerance 384
Pinilla, C., *see* Hemmer, B. 163
Poccia, F., Gougeon, M-L., Bonneville, M., Lôpez-Botet, M., Moretta, A., Battistini, L., Wallace, M., Colizzi, V. and Malkovsky, M., Innate T-cell immunity to nonpeptidic antigens 253
Poggi, A., *see* Rubartelli, A. 543
Pontesilli, O., *see* Klein, M.R. 317
Porcelli, S.A., Segelke, B.W., Sugita, M., Wilson, I.A. and Brenner, M.B., The CD1 family of lipid antigen-presenting molecules 362
Pospisil, R. and Mage, R.G., CD5 and other superantigens as 'ticklers' of the B-cell receptor 106
Prakken, B.J., *see* van Eden, W. 303
Protti, M.P. and Bellone, M., Immunotherapy: natural versus synthetic peptides (L) 98

R

Racké, K., Nitric Oxide in Health and Disease (BR) 145
Radulescu, R.T., Immune modulation by zinc: clues from immunoglobulin structure and function (L) 288
Rafferty, T.S., *see* McKenzie, R.C. 342
Raghupathy, R., Th1 and Th2 cytokines in pregnancy, from a fetal viewpoint: response to Michie (L) 333
Raz, E., *see* Tighe, H. 89
Razin, E., *see* Nechushtan, H. 441
Reid, K.B.M., Colomb, M.G. and Loos, M., Complement component C1 and the collectins: parallels between routes of acquired and innate immunity 56
Reingold, S.C., *see* Martin, R. 495
Reinhold, U., *see* Abken, H. 2
Reizis, B., Eisenstein, M., Mor, F. and Cohen, I.R., The peptide-binding strategy of the MHC class II I-A molecules 212
Resta, R., *see* Thompson, L.F. (L) 533
Revillard, J-P., Adorini, L., Goldman, M., Kabelitz, D. and Waldmann, H., Apoptosis: potential for disease therapies 291
Robins, R.A., *see* Alexandroff, A.B. 247
Rocha, B., *see* Tanchot, C. 575
Rogers, N.J., Dorling, A. and Moore, M., Xenotransplantation: steps towards a clinical reality 206
Rohrer, J.W., *see* Coggin Jr., J.H. 405
Rolink, A., *see* Osmond, D.G. 65
Rolink, A.G., *see* Ghia, P. 480
Roman, M., *see* Tighe, H. 89
Ronco, J., *see* LeClerc, C. 300
Rook, G.A.W. and Stanford, J.L., Give us this day our daily germs 113
Roopenian, D., *see* Simpson, E. 108
Rose, N.R. and Leskovsek, N., Scleroderma: immunopathogenesis and treatment 499
Rosenberg, Y.J., Anderson, A.O. and Pabst, R., HIV-induced decline in blood CD4/CD8 ratios: viral killing or altered lymphocyte trafficking? 10
Ross, C., *see* Bendtzen, K. 209
Roy, D.C., *see* Perreault, C. 69
Rubartelli, A., Poggi, A., Sitia, R. and Zocchi, M.R., HIV-1 Tat: a polypeptide for all seasons 543
Ruddle, N.H., *see* Martin, R. 495
Ruiz-Cabello, F. and Garrido, F., HLA and cancer: from research to clinical impact 539
Ruzicka, T., *see* Grewe, M. 359

S

Sacerdote, P., *see* Panerai, A.E. (L) 192
Sachs, B., *see* Griem, P. 133
Sallusto, F., Lanzavecchia, A. and Mackay, C.R., Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses 568
Salojin, K.V., Zhang, J., Madrenas, J. and Delovitch, T.L., T-cell anergy and altered T-cell receptor signaling: effects on autoimmune disease 468
Salzet, B., *see* Stefano, G.B. 265
Sánchez-Madrid, F., *see* Díaz-González, F. 169
Satoh, T., *see* Li, S. 455
Savino, W., *see* Alves, L.A. 269
Savino, W., Vermeulen, M., Dardenne, M. and Lepault, F., The thymic extracellular matrix in genetically engineered mice (L) 144
Saxena, R.K., Continuing education in immunology 437
Scala, E., *see* Paganelli, R. (L) 142
Schedlowski, M., Stress, Stress Hormones and the Immune System (BR) 535
Schiffenbauer, J., Soos, J. and Johnson, H., The possible role of bacterial superantigens in the pathogenesis of autoimmune disorders 117
Schölmerich, J., *see* Straub, R.H. 409
Schöpf, E., *see* Grewe, M. 359
Schuitemaker, H., *see* Wolthers, K.C. 44
Schulz, O., *see* Shakib, F. 313
Schwarz, T., *see* Grabbe, S. 37
Scott, H., *see* Peterson, P. 384
Segelke, B.W., *see* Porcelli, S.A. 362
Sercarz, E.E., *see* Moudgil, K.D. 217
Sewell, H., *see* Shakib, F. 313
Shakib, F., Schulz, O. and Sewell, H., A mite subversive: cleavage of CD23 and CD25 by Der p 1 enhances allergenicity 313
Shevach, E.M., *see* DosReis, G.A. (L) 587
Shimizu, N., *see* Peterson, P. 384
Siegrist, C-A., *see* Kovarik, J. 150
Sieling, P.A., *see* Fairhurst, R.M. 257
Sim, B.C., Lo, D. and Gascoigne, N.R.J., Preferential expression of TCR Vα regions in CD4/CD8 subsets: class discrimination or co-receptor recognition? 276
Simpson, E., Roopenian, D. and Goulmy, E., Much ado about minor histocompatibility antigens 108
Sitia, R., *see* Rubartelli, A. 543
Smith, R.M. and Mandel, T.E., Transplantation treatment for diabetes 444
Soos, J., *see* Schiffenbauer, J. 117
Sparshott, S.M., *see* Bell, E.B. 60
Spencer, J., Perry, M.E. and Dunn-Walters, D.K., Human marginal-zone B cells 421
Spinozzi, F., Agea, E., Bistoni, O., Forenza, N. and Bertotto, A., γδ T cells, allergen recognition and airway inflammation 22
Stallmach, A., Strober, W., MacDonald, T.T., Lochs, H. and Zeitz, M., Induction and modulation of gastrointestinal inflammation 438
Stanford, J.L., *see* Rook, G.A.W. 113
Stefano, G.B., Salzet, B. and Fricchione, G.L., Enkelytin and opioid peptide association in invertebrates and vertebrates: immune activation and pain 265
Sterry, W., *see* Farzaneh, F. 294
Sterry, W., *see* Jahn, S. 100
Stewart, J.J., The female X-inactivation mosaic in systemic lupus erythematosus 352
Straub, R.H., Westermann, J., Schölmerich, J. and Falk, W., Communication between the CNS and the immune system in lymphoid organs 409
Strobel, S. and Mowat, A. McI., Immune responses to dietary antigens: oral tolerance 173
Strober, W., *see* Stallmach, A. 438
Sugita, M., *see* Porcelli, S.A. 362
Sullivan, D.A., *see* Zierhut, M. 148

Sunyer, J.O., Zakardis, I. and Lambris, J.D., Complement diversity: a new mechanism for generating immune diversity? 519
Svenson, M., *see* Bendtzen, K. 209
Swinford, R.D., *see* Pascual, M. 514

T
Talwar, G.P., The 10th International Congress of Immunology 431
Tanchot, C. and Rocha, B., The organization of mature T-cell pools 575
Tarkowski, A., *see* Bergquist, J. 562
ten Boekel, E., *see* Ghia, P. 480
Testi, R., *see* De Maria, R. 121
Thepen, T., *see* Grewe, M. 359
Thome, M., *see* Meinl, E. 474
Thompson, E.J., *see* Laman, J.D. 489
Thompson, L.F. and Resta, R., Ecto-ADA in the development of the immune system: response to Lluis *et al.* (L) 533
Thrasher, A.J., Jones, G.E., Kinnon, C., Brickett, P.M. and Katz, D.R., Is Wiskott–Aldrich syndrome a cell trafficking disorder? 537
Tighe, H., Corr, M., Roman, M. and Raz, E., Gene vaccination: plasmid DNA is more than just a blueprint 89
Tobes, R., Pareja, E., Nieto, A. and Martin, J., Two classes of MHC class II interaction with the TCR (L) 192
Tolkoff-Rubin, N., *see* Pascual, M. 514
Trefzer, U., *see* Farzaneh, F. 294
Tremblay, M.J., Fortin, J-F. and Cantin, R., The acquisition of host-encoded proteins by nascent HIV-1 346
Tschopp, J., *see* Meinl, E. 474
Tuohy, V.K., *see* Mathisen, P.M. 103

V
Van Damme, J., *see* Opdenakker, G. 182
van den Elsen, P.J., Peijnenburg, A., van Eggermond, M.C.J.A. and Gobin, S.J.P., Shared regulatory elements in the promoters of MHC class I and class II genes 308
van der Burg, S.H., *see* Klein, M.R. 317
van der Zee, R., *see* van Eden, W. 303
van Eden, W., van der Zee, R., Paul, A.G.A., Prakken, B.J., Wendling, U., Anderton, S.M. and Wauben, M.H.M., Do heat shock proteins control the balance of the T-cell regulation in inflammatory diseases? 303
van Eggermond, M.C.J.A., *see* van den Elsen, P.J. 308
Vandenbrouke-Grauls, C.M.J.E., *see* Appelmelk, B.J. 296
Vasta, G.R., *see* Magor, K.E. 54
Vergelli, M., *see* Hemmer, B. 163
Vermeulen, M., *see* Savino, W. (L) 144
Virag, L., *see* Downing, J.E.G. (L) 190

W
Walden, P., *see* Farzaneh, F. 294
Walden, P., *see* Jahn, S. 100
Waldmann, H., *see* Revillard, J-P. 291
Wallace, M., *see* Poccia, F. 253
Walsh, L., Antigen recognition by NK cells: a role for FcRγ 53
Walsh, L., CCR5 monkey business: SIV can bypass CD4 1
Walsh, L., Evading the CTL response: the role of HIV-1 Nef 99
Wang, C-X., *see* Fairhurst, R.M. 257
Watson, S.P. and Gibbins, J., Collagen receptor signalling in platelets: extending the role of the ITAM 260
Wauben, M.H.M., *see* van Eden, W. 303
Weiss, G., Widner, B., Zoller, H. and Fuchs, D., The immunobiology of zinc and the kidney (L) 193
Weller, R., *see* McKenzie, R.C. (L) 427
Wendling, U., *see* van Eden, W. 303
Westerman, J., Bode, U. and Pabst, R., Migration of naive and memory T cells *in vivo* (L) 143
Westermann, J., *see* Straub, R.H. 409
Whyte, A., *see* Perry, M. 414
Widner, B., *see* Weiss, G. (L) 193
Wilckens, T., Steroid Hormones and the T-Cell Cytokine Profile (BR) 335
Williams, W.W., *see* Pascual, M. 514
Wilson, I.A., *see* Porcelli, S.A. 362
Wing, E.J., *see* Gregory, S.H. 507
Wolthers, K.C., Schuitemaker, H. and Miedema, F., Rapid $CD4^+$ T-cell turnover in HIV-1 infection: a paradigm revisited 44
Wulferink, M., *see* Griem, P. 133

Y
Yakura, H., Phosphatases and kinases in lymphocyte signaling 198
Yang, X., *see* Froelich, C.J. 30
Young, L.S., Eliopoulos, A.G., Gallagher, N.J. and Dawson, C.W., CD40 and epithelial cells: across the great divide 502

Z
Zakardis, I., *see* Sunyer, J.O. 519
Zeitz, M., *see* Stallmach, A. 438
Zhang, J., *see* Salojin, K.V. 468
Zierhut, M., Elson, C.O., Forrester, J.V., Kijlstra, A., Kraehenbuhl, J-P. and Sullivan, D.A., Muscosal immunology and the eye 148
Zocchi, M.R., *see* Rubartelli, A. 543
Zoller, H., *see* Weiss, G. (L) 193

Subject Index

References are to page numbers.
The suffix (L) = Letter to the Editor.
Alphabetization is letter-by-letter e.g.
T cells
T-cell vaccination

A
Accommodation
in xenotransplantation 207
Acquired immunodeficiency syndrome *see* AIDS
Activation-induced cell death (AICD) *see also* Apoptosis
Fas–FasL pathway 292
ecto ADA in immune development 533 (L)
Adhesion molecule, *see also* Selectin
acquisition by HIV-1 348
angiogenesis and cancer 392
cascade, regulation of 170–172
in allergic inflammation 8
in contact hypersensitivity 40
immunobiology of CD43 546–550
in leukocytosis 187
trafficking in tonsils 417
Affinity maturation
in germinal centre 512
AICD *see* Activation-induced cell death
AIDS, *see also* HIV
CTL activity during disease progression 319
T-cell help in 142 (L)
how effective is drug combination therapy? 528–532
Allergy
atopic dermatitis 359–361
to drugs, mechanism 196–198
γδ T cells in airway inflammation 22–26
complex disease analysis 326–327
contact hypersensitivity 37–44
enzymic activity of Der p 1 313–316
environmental factors 5 325
FcεRI expression on APC 311–313
genetic basis 5 325–332
NSAID in therapy 429 (L)
oral bacteriotherapy 486 (L)
recent advances in asthma 5–9
to xenobiotics 133–141
Anergy *see also* Tolerance
altered T-cell signalling in autoimmune disease 468–473
Angiogenesis
angiostatic drugs 394
target for tumor immunotherapy 392–394
Antigen
dietary, in oral tolerance 173–181
flanking determinants in immunogenicity 217–220
silencing in cancer 27
Antigen presentation *see also* Antigen-presenting cell
by CD1 molecules 362–367
'crosspresentation' to CTL 368–373
in gastrointestinal inflammation 438
in MS pathology 489
why are there two rat TAPs? 580–586
Antigen-presenting cell (APC), *see also* Dendritic cell, Follicular dendritic cell, Langerhans cell, Thymic dendritic cells
'crosspresentation' to CTL 371
in DNA vaccination 90
evolution of 449
new cells in self tolerance 448–454
NO and psoriasis 427 (L)
Antigen processing
in oral tolerance 175
Antiphospholipid antibodies
cell penetration by 49 (L)
Antiviral immunity
anti-apoptotic strategies of lymphotropic viruses 474–479
CTL activity in HIV-1 disease 317–324
in scleroderma 499
APC *see* Antigen presenting cell
Apoptosis
caspases in 30
lymphocyte granule-mediated 30–36
potential as immunotherapy 291–293
role of NO 558
signaling cascades in 291
of T cells, DC-mediated 190–191 (L)
virally encoded anti-apoptotic genes 475
viral inhibition of 474–479
Arthritis *see* Rheumatoid arthritis
Asthma
complex disease analysis 326–327
environmental factors 325
γδ T cells in 22–26
genetic basis 325–332
NSAID in therapy 429 (L)
recent advances 5–9
Atopy *see* Allergy
Atopic dermatitis
IL-12 in 360
Th1/Th2 cells in 359–361
Autoantibody
anticytokine therapy 210
to cytokines 209–211
Autoimmune disease, *see also* Autoimmunity, Experimental autoimmune encephalomyelitis, Insulin-dependent diabetes mellitus, Rheumatoid arthritis, Thyroiditis
10th ICI update 436
altered T-cell signalling in 468–473
autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) 384–386
pediatric rheumatology 250–253
organ specific, role of Fas–FasL 121–125
role of bacterial superantigens 117–120
role of catalytic antibodies 223
role of hsps 304
role of NO 556–561
Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED)
AIRE gene defect 384
Autoimmunity
AIRE gene defect 384
contribution of TCR degeneracy 167
failure of peripheral immune regulation 453
Helicobacter pylori in 296–299
in SLE, role of X-inactivation 352–357
to xenobiotics 133–141

B
β-endorphin
in immune cells 191–192 (L)
B cell
effects of cannabinoids 376
in human marginal zone 421–426
malignant, in marginal zone 424
superantigens 106–108
B-cell development *see also* Pre-B cell, Pro-B cell
in mouse and man, a comparison 480–485
murine, a unified model 65–68
role of ecto-ADA 533 (L)
Basophil
in asthma 6
Bioinformatics
genomic potential of molecular libraries 524–527
Bottazzo–Feldman hypothesis
pathogenesis of thyroiditis 97 (L)
Bovine spongiform encephalitis (BSE) *see* Transmissible spongiform encephalopathy

C
C1 *see also* Complement
in acquired immunity 56–59
complex 57
in innate immunity 56–59
C1q
receptors 58
deficiency 59
Cannabinoids *see* Cannabinoid receptors
Cannabinoid receptors
immune functions of 373–381
Cancer *see* Tumor immunology
Caspases
in apoptosis 30–36
Catecholamines
in immunosuppression 562–567
CD1
cell biology and biosynthesis 365
crystal structure of 363
lipid antigen presentation 257, 362–367

the 'palmitate' hypothesis 257
in T-cell independent antibody responses 257
T-cell recognition of 362–363
T-cell responses to polysaccharide antigens 257–259
CD3 *see* T-cell receptor
CD4
oligomerization, in T-cell function 455–462
in drug design 455–462
CD4 T cell
memory 60–64
memory, recirculation of 60–64
CD45R subsets 60–64
loss in HIV infection 44–48
CD5
as B-cell superantigen 106–108
in B-cell selection 107
CD23
cleavage by Der p 1 313–316
expression in germinal centre 513
CD25
cleavage by Der p 1 313–316
CD28
role in altered T-cell signalling in autoimmune disease 472
CD40 *see also* Costimulation
on carcinomas 502
function on epithelial cells 502–506
in immunotherapy 504
in tumor immunosurveillance 248
in viral mimicry 503
CD43
immunobiology of 546–550
pro- and anti-adhesive properties 546
CD45R
expression in T-cell memory 60–64
CDw78
MHC class II subset binding 486 (L)
CD94 *see also* Killer-cell inhibitory receptor
on T cells 153–157
CD95 *see also* Apoptosis, Fas
in organ-specific autoimmunity 121–125
CDR
as carrier of peptide vaccines 129
T-cell selection and MHC restriction 279
Chemokine *see also* Chemokine receptor
in asthma 6
expression by naive and memory T cells 568–569
in leukocytosis 183
regulation of lymphocyte responses in secondary lymphoid organs 571
in T-cell priming 568–574
in Th1/Th2-mediated responses 568–574
Chemokine receptor *see also* Chemokines
expression on naive and memory T cells 568–569
expression on Th1 cells 569
expression on Th2 cells 568
IFN-α or TGF-β regulated expression 571
Clinical immunology, *see also* Immunotherapy
anti-angiogenesis 393
autoantibodies to cytokines 209–211
CTL-therapy of cancer 542
immunopathogenesis and therapy of scleroderma 499–501
Clonal deletion
effect of TCR crossreactivity 398
Collagen
role of ITAM 260–264
Collectins
in acquired immunity 56–59
in innate immunity 56–59
receptors 58
Combinatorial library
genomic potential 524–527
Comparative immunology
evolution of MHC 54
Complement *see also* C1, Collectins
in acquired immunity 56–59
C3 isoform diversity 522
in fish and poikilotherms 521
in innate immunity 56–59
diversity and evolution of immune diversity 519–524
phylogeny 55, 519–521
Complementarity-determining region *see* CDR
Connexins *see* Gap junctions
Contact hypersensitivity
allergic 37–44
immunoregulation of 37–44
role of APCs 39, 289 (L)
T-cell subsets in 39
Costimulation
in contact hypersensitivity 40
in MS and autoimmunity 496
in oral tolerance 177
role in altered T-cell signalling in autoimmune disease 472
CTL, *see* Cytotoxic T lymphocyte
CTLA-4
role in altered T-cell signalling in autoimmune disease 472
Cyclosporin
chronic toxicity in renal allografts 514–519
Cytokine, *see also* IL-, TNF-α, TGF-β, IFN-
in asthma 6
anticytokine therapy 210
autoantibodies to 209–211
in autoimmunity 495
in contact hypersensitivity 40
in DNA vaccination 93
effects of cannabinoids 377
gastric, and *Helicobacter pylori* 297
gene expression, NO-induced bias 558
in gene therapy of autoimmune disease 103–105
in leukocytosis 182–184
in pregnancy 142–143 (L)
regulators of T-cell KIR expression 154
in scleroderma 499
secretion, experimental models 496
signalling, negative regulators 340
systemic balance, role of 'germs' 113–116
type I, in immunity to intracellular bacteria 491–494
viral secretion of soluble receptors 476
Cytoskeleton
disordered in WAS 537–539
Cytotoxic T lymphocyte (CTL)
activity during AIDS progression and survival 319–320
B-cell help 142 (L)
'crosspresentation' in immunity and tolerance 368–373
in HIV, current paradoxes 317–324
in DNA vaccination 90
epitope, non-traditionally derived 551–556
KIR expression in 153–157
recognition of oncofetal antigen 405–408
viral inhibition of target-cell apoptosis 477

D
Dendritic cell (DC)
activation by xenobiotics 137
in contact hypersensitivity 289 (L)
lymphoid DC 448
myeloid DC 448
in self tolerance, two distinct types 448–451
in T-cell elimination 190–191 (L)
DNA vaccine
cytokines in 93
development, new approaches 301
expressing T-cell epitopes 131
immune responses in 89–97
adjuvanticity 92

E
EAE, *see* Experimental autoimmune encephalomyelitis
Endosome
role in MHC class II function 282–287
endocytic compartment 283
Enkelytin
bactericidal activity 265
Enkephalins
bactericidal activity 265
Epithelial cell
in tonsils 414
Epitope
aggretopic hindrance 217
flanking residues in immunogenicity 217–220
Evolution *see also* Comparative immunology
ancient and modern immunity 451
of complement diversity 519–524
of IgSF receptor family 54
of MHC 54
of rat TAP allelism 583
of tonsils 416
Exercise
and cancer 205
and immunology 204–206
neuroendocrine regulation 204
and nutrition 205
salivary IgA in athletes 204
Experimental autoimmune encephalomyelitis (EAE)
role of bacterial superantigens 117
Extracellular matrix (ECM)
immunobiology of CD43 546–550
thymic, in transgenic mice 144–145
Eye
mucosal immunology of 148–150

F
Fas *see also* Apoptosis, Fas ligand, CD95
in organ-specific autoimmunity 121–125
Fas ligand (FasL)
in organ-specific autoimmunity 121–125
FcεRI
genetic influence on allergy 327
Follicular dendritic cell (FDC)
in germinal centre structure 511–514

G
γδ T cell
in allergic inflammation 22–26
innate immunity to non-peptidic antigens 254
in infectious disease 254
recognition of xenobiotics 139
Gap junctions
experimental methodologies 269
in invertebrate immunity 269
novel route for cell–cell communication 269–275
Gene therapy *see also* Immunotherapy
of autoimmune disease 103–105
of cancer 294–296
in osteoarticular disease 387–391
in RA 387
T-cell mediated 103
Genomics
tapping the potential of molecular libraries 524–527
Germinal centre (GC)
affinity maturation in 512
development 511
dynamic structure 511–514
human MZ B cells 421–426
in tonsils 416
Graft-versus-host disease (GVHD)
minor histocompatibility antigens and 72
Granzyme B
in lymphocyte apoptosis 30–36
Gut-associated lymphoid tissue (GALT) *see* Mucosal immunology, Oral tolerance

H
Hashimoto's disease *see* Thyroiditis
Heat shock protein (Hsp)
in arthritis 304
in innate immunity 50 (L)
T-cell regulation in inflammatory disease 303–307
Hematopoiesis *see also* Lymphopoiesis
in mammalian embryo development 228–236
molecular signals in 233
in mouse 236
in PAS/AGM 229
types of progenitor cells 229–231, 237–239
in yolk sac 228
High endothelial venules (HEV)
migration of memory T cells 143 (L)
Highly active antiretroviral therapy (HAART)
in HIV disease 528–532
HIV *see also* AIDS
acquisition of host-encoded proteins 346–351
CD4 T-cell turnover 44–48
concurrent TB infection 463
CTL activity, current paradoxes 317–324
decline in CD4/CD8 ratios 10–17
entry and replication in tonsils 418
gp41, common epitope with IFN-α and -β 587 (L)
how effective is drug combination therapy? 528–532
lymphocyte migration in 10
modulation of apoptosis 478
persistence during antiviral response 320–322
role of chronically infected cells 531
role of latently infected cells 531
telomere length, loss of 45
tat, immunobiology of 543–545
viral-load kinetics 528
HLA
and cancer 539–542
HLA-DQ
peptide-binding specificity of 213
in IDDM 288–289 (L)
Human immunodeficiency virus *see* HIV

I
Idiotype *see* Epitope
IDDM *see* Insulin-dependent diabetes mellitus
IFN-α
common epitope with gp41 587 (L)
IFN-β
common epitope with gp41 587 (L)
in pregnancy 333–334 (L)
IFN-γ
role in chemokine receptor expression 571
-R1 and -R2, in immunodeficiency 491
IgD
expression in marginal zone B cells 421–426
IgE
genetic influence on allergy 327
IgG2a
possible Th1 marker 49 (L)
IgM
expression in marginal zone B cells 425
IκB
regulation of NF-κB 80–84
kinase (IKK) 82–85
IL-1
in leukocytosis 183
IL-4
genetic linkage in allergy 329
IL-6
in splenic control of neurons 411
IL-8
in leukocytosis 183
IL-12
in atopic dermatitis 360
-Rβ1, deficiency in mycobacterial infection 492
-p40, deficiency in mycobacterial infection 493
IL-15
bioactivity of 76
in RA 75–79
TNF-α and 76
Immune deviation
role of MHC 157–163
Immune evasion, *see also* Molecular mimicry
anti-apoptotic strategies of lymphotropic viruses 474–479
of HIV 320, 346–351
HLA-deficient tumors 540
NK-cell evasion by tumors 540
by tumors 249
Immunodeficiency *see also* AIDS, Wiskott–Aldrich syndrome
type I cytokines in immunity to intracellular bacteria 491–494
Immunodominance
mechanism of 71
of minor histocompatibility antigens 69–74
Immunogenetics
genomic potential of molecular libraries 524–527
Immunoglobulin (Ig) *see also* Autoantibody
secretory, in tonsils 416
zinc in immune modulation 288 (L)
Immunoglobulin genes
in B-cell development 65–68, 480–485
evolution of 54
Immunoisolation
in IDDM 445
Immunoreceptor tyrosine-based activation motifs (ITAM)
collagen receptor signalling in platelets 260–264
Immunosuppression
by catecholamines 562–567
Immunotherapy *see also* Clinical immunology
of allergic disorders 9
by apoptosis 291–293
via CD40 504
of cutaneous malignant melanoma 100–103
of cancer 2–5, 28, 294
natural versus synthetic peptides 98 (L)
oral bacteriotherapy 486 (L)
in pediatric rheumatology 250–253
in RA 389
using oral antigens 179
site directed 17–22
Inflammation *see also* Immunotherapy
airway 22–26
alternative anti-inflammatory pathways 169
control using NSAIDs 169
gastrointestinal 438–441
molecular basis of leukocytosis 182–189
role of Hsps in T-cell regulation 303–307
Inflammatory bowel disease
immunomodulatory strategies 440
Innate immunity
acquired wisdom in 50 (L)
phylogeny of complement system 55
role of C1 56–59
role of collectins 56–59
Insulin-dependent diabetes mellitus (IDDM)

role of bacterial superantigens 118
genetics of 288–289 (L)
role of Fas–FasL 121
transplantation treatment 444–447
Interferon (IFN-) *see* IFN-α, β, γ
International Congress of Immunology (ICI)
10th, New Delhi 431–437
continuing education 437
Intraepithelial lymphocytes *see also* γδ T cell
in gastrointestinal inflammation 438
ITAM *see* Immunoreceptor tyrosine-based activation motifs

J
Janus protein tyrosine kinase (JAK)
immunobiology of 338–341

K
Kawasaki's disease
role of bacterial superantigens 118
Keratinocytes
NO and psoriasis 427 (L)
Killer-cell inhibitory receptor (KIR)
regulation in human T cells 153–157
T-cell response to tumors 541
KIR, *see* Killer-cell inhibitory receptor
Kupffer cell
in blood clearance 507
–neutrophil interactions in systemic immunity 507–510

L
Langerhans cells *see also* Antigen-presenting cells
NO and psoriasis 427 (L)
Leukocyte adhesion
inhibition, using anti-inflammatory drugs 169–181
in leukocytosis 185–187
Leukocyte migration
control by chemokines 568
in leukocytosis 185–187
multistep model of 169
Leukocytosis
molecular basis of 182–189
induction of 182
Lipid
dietary, and immunomodulation 244–247
Listeriosis
model of systemic infection 507
Liver
neutrophil–Kupffer cell interactions 507–510
Lymph node
lymphocyte subsets in HIV/SIV 13–15
Lymphocyte migration *see also* Leukocyte migration
in HIV 10–13
impaired in WAS 537–539
of naive and memory T cells 143 (L)
Lymphocyte trafficking *see* Leukocyte migration, Lymphocyte migration
Lymphoid development
self tolerance during ontogeny 452
Lymphoma
cutaneous malignant 100–103
Lymphopoiesis *see also* Hematopoiesis
age-related changes in bone marrow 484
Lysosome
role in MHC class II function 282–287
endocytic compartment 283

M
Macrophage
effects of cannabinoids 377
Major histocompatibility complex (MHC), *see also* MHC class I, MHC class II
10th ICI update 434–435
acquisition by HIV-1 348
contribution to TCR affinity 164
evolution of 54
innate immunity to non-peptidic antigens 253
preferential selection of TCR Vα regions 276–282
selection of Th1/Th2 immunity 157–163
soluble HLA antigens 154–155
Mannose-binding lectin (MBL)
deficiency 59
and MASP 58
Marginal zone (MZ)
extrasplenic 422
human MZ B cells 421–426
Maternal-fetal interface *see also* Neonatal immunity, Reproductive immunology
T-cell modulation in decidua 142–143 (L)
Th1/Th2 cytokines in pregnancy 333–334 (L)
Mast cell
in asthma 6
early response transcription factors 441–444
Mathematical model *see* Quantitative model
Memory *see* T-cell memory
MHC, *see* Major histocompatibility complex
MHC class I
CIITA 308
'crosspresentation' of CTL antigens 369
crossreactive TCR recognition 399
CTL recognition of limiting MHC–peptide complexes 552
gene regulation 308–312
interaction with TAP 581
promoters, structure 309
T-cell vaccines and 129
why are there two rat TAPs? 580–586
MHC class II
alternate epitopes 555
biosynthetic pathway 282–285
and CD4 oligomerization 455–462
a clustered subset of molecules 486 (L)
elusive binding specificity 212
gene regulation 308–312
genetic linkage in allergy 329
peptide binding strategy of 212–216
promoters, structure 309
role of endosomes and lysosomes 282–287
T-cell interactions, two classes 192 (L)
T-cell vaccines and 130
Minor histocompatibility antigens
cryptic 71
genetics of 108
GVHD and 72
immunodominance of 109
immunodominant 69–74
in immunomodulation 110
molecular definition of 69–74
recognition of 110
Molecular mimicry
contribution of TCR degeneracy 167
of perforin 31
viral, in CD40-mediated signalling 503
MS, *see* Multiple sclerosis
Mucosal immunology
and the eye 148–150
downregulation of mucosal response 439
gastrointestinal inflammation 438–441
Helicobacter pylori and autoimmunity 296–299
oral bacteriotherapy 486 (L)
oral tolerance 173–181
response to dietary antigens 173–181
Multiple sclerosis (MS)
antigen presentation in 489
etiology 251
pathogenesis, role of Fas–FasL 122
pathology 489
Mycobacteria
and immune balance 114

N
Natural killer (NK) cell, *see also* Killer-cell inhibitory receptor
effects of cannabinoids 377
tumor evasion of 541
Neonatal immunity, *see also* Maternal–fetal interface
humoral responses 151
innate immunity 150–154
neonatal organ donors 445
T-cell responses 150
Neuroendocrine immunology *see* Neuroimmunology
Neuroimmunology
CNS–immune dialogue in lymphoid organs 409–413
and exercise 204
immune modulation of nerve terminals 410
immunosuppression by catecholamines 562–567
immunotherapy in 17–22
neuroinflammation 17–22
in spleen 409
Neutrophil
–Kupffer cell interactions in systemic immunity 507–510
NF-κB
signal transduction 80–88
regulation by IκB 80–81
Nitric oxide (NO)
APCs and psoriasis 427 (L)
as cytotoxic effector 556

iNOS inhibition and disease development 557
as regulator of apoptosis 558
as regulator of lymphocyte migration 559
role in autoimmune disease 556–561
in T-cell death 190–191 (L)
NKG2A *see also* Killer-cell inhibitory receptor
on T cells 153–157
Nutrition
dietary lipids and immunomodulation 244–247
immunology and exercise 205
selenium and immune function 342–345

O
Oncofetal antigen
low-dose protection 405
Opioids
pain and immune activation 265–268
Oral tolerance
to dietary antigens 173–181
factors influencing 173
in scleroderma 501
Oxidative stress *see also* Apoptosis
protective effects of selenium 342

P
Pain
cannabinoid receptors and immunity 373–381
in immune activation 265–268
opioid peptides 265
Parasite immunity
granulomatous transmission of schistosomiasis and tuberculosis 462–467
Peptide
-based CD4 inhibitors 460
combinatorial libraries 163–168
concentration and TCR crossreactivity 400
contribution to TCR affinity 164
loading of MHC class II 285–286
MHC class II binding strategies 212–216
recognition, role in memory T-cell survival 578–579
as T-cell vaccine 127
transport, role of TAP 580–586
Perforin *see also* Granzyme B
in lymphocyte apoptosis 30–36
viral mimicry of 31
Peripheral tolerance
apoptosis in 292
role of Hsps 305–307
Phage-display *see* Combinatorial library
Platelet
role of ITAM in signalling 260–264
Platelet-derived growth factor (PDGF)
in progression of renal disease 515
Positive selection
high-level TCR crossreactivity 396
Pre-B cell
first wave of Ig rearrangement 480
Pre-B-II cell
small, a second wave of Ig rearrangement 483
Pro-B cell
role of surrogate light chain 481
Progenitor B cells
commitment to B-cell lineage 480
Programmed cell death *see* Apoptosis
Pro-opiomelanocortin (POMC)
in immune cells 191–192 (L)
Prostaglandins
dietary lipids and immune modulation 244–247
in pregnancy 142–143 (L)
Protein tyrosine kinase (PTK) *see also* Signaling
in lymphocyte signaling 198–201
Protein tyrosine phosphatase (PTP) *see also* Signaling
CD45 function 199
in lymphocyte signaling 198–201
PEP 199
PTP-PEST 199
PTP substrates 198
SHP-1 199
SHP-2 199
TC-PTP 200
Psoriasis
APCs and NO production 427 (L)
role of CD40 504

Q
Quantitative model
for high-level TCR crossreactivity 395–404, 428 (L)
HIV kinetics 528

R
Reproductive immunology
10th ICI update 433–434
Rheumatoid arthritis (RA)
gene therapy in 389–391
Hsps in 304
pediatric 250–253
role of bacterial superantigens 118
role of IL-15 75–79
role of TNF-α 76

S
SAg, *see* Superantigen
Schistosomiasis
granulomatous transmission and tuberculosis 462–467
Scleroderma
immunopathogenesis 499–501
therapy 499–501
Selectin, *see* Adhesion molecule
Selenium
in immune function 342–345
antiviral effects 344
SHP-1
in lymphocyte signaling 198–201
SHP-2
in lymphocyte signaling 198–201
Signaling
collagen receptor in platelets 260–264
in apoptosis 35
JAK–STAT immunobiology 338–341
TCR, altered in autoimmune disease 468–473
transcription factors in mast cells 441–444
via kinases 198–201
via phosphatases 198–201
Somatic mutation
in superantibodies 223
STAT
immunobiology of 338–341
Stem cells *see also* Hematopoiesis
developmental requirements 239–240
differentiation capacity 236–241
localization and migration 232
plasticity of 239
Superantigen (SAg)
B cell 106–108
CD5 as 106–108
bacterial, in autoimmune disease 117–120
and superantibodies 225
Superantibody
catalytic activities 221
germline origin 222
in innate and adaptive immunity 221–227
nucleotide binding 224
self-binding 225
somatic mutation 223
superantigen binding 225
V-domain substructures 221
Systemic lupus erythematosus (SLE)
female X-inactivation in 352–357
lines of Blaschko 354
xenobiotic metabolism and 136

T
T cell *see also* γδ T cell
anergy, characteristics 468
effects of cannabinoids 375
innate immunity to non-peptidic antigens 253–256
maintenance of mature T cells 576
pools, organization of 575–579
T-cell activation
role of CD4 oligomerization 457
by xenobiotics 137–139, 196
in xenotransplantation 207
T-cell development
from memory to effector function 579
role of ecto-ADA 533 (L)
T-cell epitope *see also* Epitope
flanking residues and immunogenicity 217–220
N-terminal residue processing 218
as vaccines 126–133
T-cell epitope
CTL, non-traditionally derived 551–556
T-cell memory
CD45R subsets 60–64
cell migration in 143 (L)
in DNA vaccination 91
persistence, a unifying concept 60–64
regulation of naive and memory pools 576
role of antigen 60–64
T-cell migration
in neural inflammation 17–22
naive versus memory 143 (L)
T-cell receptor (TCR)
altered signalling in autoimmune disease 468–473
continuous ligation in peripheral T cells 575
degeneracy in 163–168

high levels of crossreactivity are essential 395–404, 428 (L)
–MHC class II interactions 192 (L)
preferential Vα expression in CD4/CD8 T cells 276–282
structural basis of CD4–MHC class II interactions 458
T-cell repertoire
degeneracy in 163–168
essential crossreactivity 395–404, 428 (L)
in larger species 399
probing with peptide combinatorial libraries 163–168
role of 'germs' in shaping 115
role of MHC genotype 157–163
T-cell selection
essential TCR crossreactivity 395–404, 428 (L)
preferential selection of TCR Vα regions 276–282
in SLE 354
T-cell tolerance, *see* Peripheral tolerance, Tolerance
TAP
rat, why are there two? 580–586
TCR, *see* T-cell receptor
TCR repertoire, *see* T-cell repertoire
Techniques
capillary electrophoresis 563
Telomere
loss in HIV infection 44–48
TGF-β
in progression of renal disease 515
role in chemokine receptor expression 571
Th1/Th2 balance
APC and costimulation 160
antigen dose 158
in autoimmunity 495
exposure to 'germs' 113–116
NO-induced bias 558
in pregnancy 333–334 (L)
in MS 489–490, 495–498
role of MHC 157–163
Th1 cell
in atopic dermatitis 359–361
B-cell help 142 (L)
chemokine and chemokine receptor expression 569
IgG2a, a possible marker 49 (L)
pertussis infection and 534 (L)
response to DNA vaccination 89
in tumor responses 249
Th2 cell
in atopic dermatitis 359–361
B-cell help 142 (L)
chemokine and chemokine receptor expression 569
Thalidomide
use in scleroderma 500
Thymic dendritic cells
skewing in SLE 352–357
Thymic epithelium
in transgenic mice 144–145
Thyroiditis
Bottazzo–Feldman hypothesis 97 (L)
pathogenesis of, role of Fas–FasL 124
TNF-α
IL-15 and 76
in pregnancy 333–334 (L)
in splenic control of neurons 411
Tolerance, *see also* Anergy, Oral tolerance, Peripheral tolerance
in SLE, role of X-inactivation 352
role of epitope flanking residues 217–220
self, evolution of 448–451
Tonsils
immunology of 414–421
Transcription factors
AP-1 in mast cells 441
USF2 in mast cells 442
Transforming growth factor β *see* TGF-β
Transmissible spongiform encephalopathy (TSE)
immune intervention in 202
immune pathogenesis 201–203
mode of infection 201
trans-species infection 202
Transplantation *see also* Xenotransplant
avoiding chronic allograft injury 517
chronic cyclosporin toxicity in renal allografts 514–519
in IDDM 444–447
minor histocompatibility antigens 72
pancreas versus islet allografts 444
Transporter of antigen presentation (TAP)
allelic evolution 580
rat, structure and function 580–586
Tuberculosis (TB)
concurrent HIV infection 463
granulomatous transmission and schistosomiasis 462–467
Tumor-associated antigen (TAA) *see also* Vaccines
in peptide immunotherapy 98 (L)
MAGE 540
Tumor immunology *see also* Tumors associated antigen
antibody-based therapy 2–5, 247
CD40 in immune surveillance 248
cutaneous malignant melanoma 100–103
effects of exercise 205
HLA and cancer 539–542
immune evasion 27–30
marginal zone B-cell malignancy 425
oncofetal antigen 405–408
polarized Th1 response 249
T-cell based therapy 2–5
tumor-specific transplantation antigens 405–408
vasculature-directed therapy 392–394
Tumor immunotherapy
antibody based 247
gene therapy in 294–296
inhibition of angiogenesis 295
T-cell based 2–5
vasculature-directed therapy 392–394
Tumor necrosis factor *see* TNF-α

V
Vaccines *see also* DNA vaccine
adjuvants in humans 300
effects of exercise 204
development, new approaches 300–302
live vectors 302
pertussis and Th1 cells 534 (L)
role of 'germs' 113–116
in scleroderma 499
T cell, development of 126–133
Viral immunology *see* Antiviral immunity

W
Waldeyer's ring
immunology of tonsils 414–421
Wiskott–Aldrich syndrome
a cell trafficking disorder? 537–539

X
X-chromosome inactivation
in SLE 352–357
Xenobiotics
in allergy and autoimmunity 133–141, 196–198
crossreactivity of betalactam antibiotics 197
hepatic metabolism of 134–135
phagocytic metabolism 135
sensitization to 136
T-cell recognition of 137–139, 196
Xenotransplant
accommodation 207
delayed xenograft rejection 207
hyperacute rejection 206
in IDDM 445
infectious hazards 208
tolerance 207
towards clinical reality 206–208

Z
Zinc
immunobiology of 193 (L)
in immune modulation 288 (L)